2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-161844
    Virapinib
    		Inhibitor
    Virapinib is a macropinocytosis inhibitor with antiviral activity. Virapinib exhibits broad-spectrum antiviral activity against SARS-CoV-2, monkeypox virus, tick-borne encephalitis virus, and Ebola pseudotyped vesicular stomatitis virus, and it enhances Dengue Virus infection. Virapinib blocks viral entry by inhibiting macropinocytosis, reduces syncytium formation in SARS-CoV-2-infected cells, and impairs cellular entry of SARS-CoV-2 variants. Virapinib upregulates the expression of genes related to sterol biosynthesis. Virapinib can be used in studies related to COVID-19, monkeypox, tick-borne encephalitis, and Ebola virus infection.
    Virapinib
  • HY-174350
    CK2-IN-15
    		Inhibitor
    CK2-IN-15 (Compound Biv5) is a selective and potent bivalent protein kinase CK2 inhibitor with an IC50 value of 51 pM. CK2-IN-15 significantly reduces the replication of SARS-CoV-2 in HEK-ACE2-TMPRSS2 and Vero cells, and also reduces viral replication in an ex vivo model of human nasal epithelial cells. CK2-IN-15 is promising for research of β-coronavirus infection-related diseases.
    CK2-IN-15
  • HY-144464
    SARS-CoV-2 Mpro-IN-1
    		Inhibitor
    SARS-CoV-2 Mpro-IN-1 (compound 16b-3) is a potent, selective and irreversible inhibitor of SARS-CoV-2 main protease (Mpro), with an IC50 of 116 nM.
    SARS-CoV-2 Mpro-IN-1
  • HY-149362
    MTase-IN-1
    		Inhibitor
    MTase-IN-1 (compound 26) is a potent and selective inhibitor of coronavirus nsp14 N7-methyltransferases, with an IC50 of 0.72 nM. MTase-IN-1 impairs viral RNA translation and immune evasion.
    MTase-IN-1
  • HY-149774
    GC-78-HCl
    GC-78-HCl is an orally and nonpeptidic SARS-CoV-2 Mpro inhibitor, with an IC50 of 0.19 μM for enzyme. GC-78-HCl has excellent antiviral activity and favorable pharmacokinetic properties.
    GC-78-HCl
  • HY-W777545
    4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4
    4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d4 is the deuterium labeled Hydroxychloroquine Impurity E (HY-131262). Hydroxychloroquine Impurity E is the impurity of Hydroxychloroquine. Hydroxychloroquine is a synthetic antimalarial agent which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling. Hydroxychloroquine is efficiently inhibits SARS-CoV-2 infection in vitro.
    4-[(7-Chloro-4-quinolinyl)amino]-1-pentanol-d<sub>4</sub>
  • HY-P992282
    Anti-Nucleocapsid Antibody (N-P10)
    		Inhibitor
    Anti-Nucleocapsid Antibody (N-P10) is a highly specific SARS-CoV-2 Nucleocapsid (N) protein-targeted recombinant monoclonal antibody. Anti-Nucleocapsid Antibody (N-P10) can be used for research on SARS-CoV-2 infection.
    Anti-Nucleocapsid Antibody (N-P10)
  • HY-157021
    SARS-CoV-2-IN-66
    		Inhibitor
    SARS-CoV-2-IN-66 (1), a vitaminK derivative, is a SARS-CoV-2 inhibitor, with an EC50 of 70.8 μM in VeroE6/TMPRSS2 cells.
    SARS-CoV-2-IN-66
  • HY-151276A
    SARS-CoV-2-IN-29 disodium
    		Inhibitor
    SARS-CoV-2-IN-29 disodium is a two-armed diphosphate ester with benzene system and molecular tweezers. SARS-CoV-2-IN-29 disodium exhibits antiviral activity with IC50s of 1.5 μM and 1.6 μM against SARS-CoV-2 activity and the spike pseudoparticle transduction, respectively. SARS-CoV-2-IN-29 disodium induces liposomal membrane disruption with an EC50 value of 3.0 μM.
    SARS-CoV-2-IN-29 disodium
  • HY-150680
    SARS-CoV-2 nsp14-IN-1
    		Inhibitor
    SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases.
    SARS-CoV-2 nsp14-IN-1
  • HY-169224
    SARS-CoV-2-IN-100
    		Inhibitor
    SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2 variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance.
    SARS-CoV-2-IN-100
  • HY-181263
    Jun13698
    		Inhibitor
    Jun13698 is a SARS-CoV-2 main protease (Mpro) inhibitor with Ki values of 65.6 nM, 510.0 nM, and 117.5 nM against the wild-type, E166V, and E166A mutants, respectively. Jun13698 forms stable complexes with wild-type and mutant Mpro to mediate enzyme inhibition. Jun13698 exhibits antiviral activity against SARS-CoV-2 variants carrying the E166V/A mutation. Jun13698 is applicable to COVID-19-related research.
    Jun13698
  • HY-W423489
    SARS-CoV-2-IN-76
    		Inhibitor
    SARS-CoV-2-IN-76 (compound 1) is a nsp14-viral cap N7 methyltranferase and PLpro inhibitor of severe acute respiratory syndrome corona virus (SARS-CoV-2).
    SARS-CoV-2-IN-76
  • HY-177663
    SARSi-4 sodium
    		Inhibitor
    SARSi-4 sodium is a siRNA that markedly inhibited the replication of SARS-associated coronavirus (SCoV).
    SARSi-4 sodium
  • HY-179249
    Fluoroneplanocin A-8N
    		Inhibitor
    Fluoroneplanocin A-8N (Compound 3a) is an inhibitor targeting SAH hydrolase (IC50 = 1.51 μM) and viral RNA polymerase. Fluoroneplanocin A-8N exhibits broad-spectrum anti-SARS-CoV-2 and dengue virus activity, with EC50 values of 12.2 and 37.4 μM respectively. Fluoroneplanocin A-8N has no cytotoxicity. Fluoroneplanocin A-8N can be used for anti-positive-strand viruses.
    Fluoroneplanocin A-8N
  • HY-N5068
    Isorhamnetin 7-O-α-L-rhamnoside
    Isorhamnetin 7-O-α-L-rhamnoside shows binding affinity with COVID-19 virus main protease.
    Isorhamnetin 7-O-α-L-rhamnoside
  • HY-162236
    SARS-CoV-2-IN-80
    		Inhibitor
    SARS-CoV-2-IN-80 (compound 13) is a potent SARS-CoV-2 3CLpro inhibitor with an IC50 value of 0.964 µM.
    SARS-CoV-2-IN-80
  • HY-10235R
    Telaprevir (Standard)
    		Inhibitor
    Telaprevir (Standard) is the analytical standard of Telaprevir. This product is intended for research and analytical applications. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide. Telaprevir inhibits SARS-CoV-2 3CLpro activity.
    Telaprevir (Standard)
  • HY-161902
    MI-1904
    		Inhibitor
    MI-1904 is the inhibitor for matriptase/TMPRSS2, that exhibits antiviral activity against influenza virus H1N1 and H9N2. MI-1904 blocks the cleavage of glycoproteins on the viral surface, prevents the virus from binding to host cell receptors, and thus inhibits the entry and replication of the virus.
    MI-1904
  • HY-162154
    SARS-CoV-2-IN-75
    		Inhibitor
    SARS-CoV-2-IN-75 (compound 13) is a SARS-CoV-2 inhibitor based on chloroacetamide inhibition. SARS-CoV-2-IN-75 inhibits cellular SARS-CoV-2 replication with an EC68 (half-log reduction in viral titer) of 3 μM.
    SARS-CoV-2-IN-75
Cat. No. Product Name / Synonyms Species Source